182 related articles for article (PubMed ID: 7872323)
1. Influence of dialysis modality on plasma and tissue concentrations of pentosidine in patients with end-stage renal disease.
Friedlander MA; Wu YC; Schulak JA; Monnier VM; Hricik DE
Am J Kidney Dis; 1995 Mar; 25(3):445-51. PubMed ID: 7872323
[TBL] [Abstract][Full Text] [Related]
2. Kinetic analysis of furosine and pentosidine in CAPD patients.
Kumano K; Yokota S; Sakai T; Kobayashi N; Yoshida A; Yoshihara T; Shibata K; Izumi G; Wang H
Adv Perit Dial; 1997; 13():53-7. PubMed ID: 9360651
[TBL] [Abstract][Full Text] [Related]
3. Disparate changes in plasma and tissue pentosidine levels after kidney and kidney-pancreas transplantation.
Hricik DE; Wu YC; Schulak A; Friedlander MA
Clin Transplant; 1996 Dec; 10(6 Pt 1):568-73. PubMed ID: 8996781
[TBL] [Abstract][Full Text] [Related]
4. [Reduction of carbonyl stress with renal replacement therapy in chronic renal failure].
Słowik-Zyłka D
Ann Acad Med Stetin; 2004; 50(2):5-15. PubMed ID: 16529161
[TBL] [Abstract][Full Text] [Related]
5. The advanced glycation endproduct pentosidine and monocyte activation in uremia.
Friedlander MA; Witko-Sarsat V; Nguyen AT; Wu YC; Labrunte M; Verger C; Jungers P; Descamps-Latscha B
Clin Nephrol; 1996 Jun; 45(6):379-82. PubMed ID: 8793229
[TBL] [Abstract][Full Text] [Related]
6. Plasma pentosidine levels in uremic patients before and after hemodialysis.
Takahashi M; Kushida K; Ishihara C; Denda M; Inoue T
Scand J Urol Nephrol; 1995 Jun; 29(2):131-4. PubMed ID: 7569788
[TBL] [Abstract][Full Text] [Related]
7. Effect of the peritoneal dialysis prescription on pentosidine in children.
Bayazit AK; Vogt BA; Dell KM; Davis ID; Noyan A; Anarat A; Avner ED; Erhard P; Weiss MF
Pediatr Nephrol; 2003 Oct; 18(10):1049-54. PubMed ID: 12898376
[TBL] [Abstract][Full Text] [Related]
8. Clearance of pentosidine, an advanced glycation end product, by different modalities of renal replacement therapy.
Miyata T; Ueda Y; Yoshida A; Sugiyama S; Iida Y; Jadoul M; Maeda K; Kurokawa K; van Ypersele de Strihou C
Kidney Int; 1997 Mar; 51(3):880-7. PubMed ID: 9067925
[TBL] [Abstract][Full Text] [Related]
9. Plasma pentosidine and total homocysteine levels in relation to change in common carotid intima-media area in the first year of dialysis therapy.
Suliman ME; Stenvinkel P; Jogestrand T; Maruyama Y; Qureshi AR; Bárány P; Heimbürger O; Lindholm B
Clin Nephrol; 2006 Dec; 66(6):418-25. PubMed ID: 17176913
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of advanced glycation end products and carbonyl compounds in patients with different conditions of oxidative stress.
Lapolla A; Reitano R; Seraglia R; Sartore G; Ragazzi E; Traldi P
Mol Nutr Food Res; 2005 Jul; 49(7):685-90. PubMed ID: 15926142
[TBL] [Abstract][Full Text] [Related]
11. Ultrapure dialysate decreases plasma pentosidine, a marker of "carbonyl stress".
Izuhara Y; Miyata T; Saito K; Ishikawa N; Kakuta T; Nangaku M; Yoshida H; Saito A; Kurokawa K; van Ypersele de Strihou C
Am J Kidney Dis; 2004 Jun; 43(6):1024-9. PubMed ID: 15168382
[TBL] [Abstract][Full Text] [Related]
12. Association between Asymmetric Dimethylarginine and Pentosidine in Dialysis Effluent of Peritoneal Dialysis Patients -A possible intraperitoneal crosstalk between asymmetric dimethylarginine and advanced glycation end products in peritoneal dialysis patients.
Ishida M; Kakuta T; Miyakogawa T; Tatsumi R; Matsumoto C; Fukagawa M
Tokai J Exp Clin Med; 2016 Jun; 41(2):97-100. PubMed ID: 27345001
[TBL] [Abstract][Full Text] [Related]
13. Effects of kidney or kidney-pancreas transplantation on plasma pentosidine.
Hricik DE; Schulak JA; Sell DR; Fogarty JF; Monnier VM
Kidney Int; 1993 Feb; 43(2):398-403. PubMed ID: 8441235
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms for the formation of glycoxidation products in end-stage renal disease.
Weiss MF; Erhard P; Kader-Attia FA; Wu YC; Deoreo PB; Araki A; Glomb MA; Monnier VM
Kidney Int; 2000 Jun; 57(6):2571-85. PubMed ID: 10844627
[TBL] [Abstract][Full Text] [Related]
15. Advanced glycation end products: specific fluorescence changes of pentosidine-like compounds during short daily hemodialysis.
Fagugli RM; Vanholder R; De Smet R; Selvi A; Antolini F; Lameire N; Floridi A; Buoncristiani U
Int J Artif Organs; 2001 May; 24(5):256-62. PubMed ID: 11420874
[TBL] [Abstract][Full Text] [Related]
16. Influence of dialysis modalities on serum AGE levels in end-stage renal disease patients.
Stein G; Franke S; Mahiout A; Schneider S; Sperschneider H; Borst S; Vienken J
Nephrol Dial Transplant; 2001 May; 16(5):999-1008. PubMed ID: 11328907
[TBL] [Abstract][Full Text] [Related]
17. Advanced glycation and lipidoxidation of the peritoneal membrane: respective roles of serum and peritoneal fluid reactive carbonyl compounds.
Miyata T; Horie K; Ueda Y; Fujita Y; Izuhara Y; Hirano H; Uchida K; Saito A; van Ypersele de Strihou C; Kurokawa K
Kidney Int; 2000 Jul; 58(1):425-35. PubMed ID: 10886591
[TBL] [Abstract][Full Text] [Related]
18. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure.
Miyata T; Wada Y; Cai Z; Iida Y; Horie K; Yasuda Y; Maeda K; Kurokawa K; van Ypersele de Strihou C
Kidney Int; 1997 Apr; 51(4):1170-81. PubMed ID: 9083283
[TBL] [Abstract][Full Text] [Related]
19. Early and advanced glycosylation end products. Kinetics of formation and clearance in peritoneal dialysis.
Friedlander MA; Wu YC; Elgawish A; Monnier VM
J Clin Invest; 1996 Feb; 97(3):728-35. PubMed ID: 8609229
[TBL] [Abstract][Full Text] [Related]
20. Effects of continuous ambulatory peritoneal dialysis and kidney transplantation on advanced glycation endproducts in the skin and peritoneum.
Shaw S; Akyol M; Bell J; Briggs JD; Dominiczak MH
Cell Mol Biol (Noisy-le-grand); 1998 Nov; 44(7):1061-8. PubMed ID: 9846888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
